35% af de 579 patienter, som blev behandlet med sapropterindihydrochlorid (5 – 20 mg/ kg/ daglig) i de kliniske forsøg med Kuvan oplevede bivirkninger.
Approximately 35% of the 579 patients who received treatment with sapropterin dihydrochloride (5 to 20 mg/ kg/ day) in the clinical trials for Kuvan experienced adverse reactions.